# Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)

> **NCT00340574** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Healthy Volunteer
- HV

## Interventions

- **DRUG:** AMA1-C1/Alhydrogel + CpG 7909

## Key facts

- **NCT ID:** NCT00340574
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-08
- **Primary completion:** —
- **Final completion:** 2008-07-02
- **Target enrollment:** 0 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00340574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00340574, "Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00340574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*